Saturday 17 October 2026
Export TNON’s income statement to Excel — free account
Tenon Medical, Inc.
TNON Healthcare Medical Devices
Tenon Medical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue grew 126.8%, EPS grew 1.88% and free cash flow fell 21.8%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
2.70
0.21
−7.22%
Follow TNON
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 5 | 4 | 6 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(13.00) | (12.93) | (19.42) | (8.17) | — | — | — |
P/S ratio |
1.78 | 0.70 | 0.96 | 18.68 | 116.67 | 116.67 | 116.67 |
Altman Z″-Score (non-manufacturers) |
(29.53) | (26.32) | (44.03) | (17.57) | (17.74) | (67.84) | (110.23) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(3.16) | (0.82) | (1.24) | (3.81) | (10.23) | (10.23) | (10.23) |
Beneish M-Score |
(1.81) | (3.89) | (3.76) | — | (1.46) | (9.71) | — |
P/B ratio |
3.58 | 1.03 | 3.63 | 2.07 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 1.03 | 3.63 | 2.07 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.92 | (1.20) | 0.25 | 6.77 | 96.56 | 96.56 | 96.56 |
EV/EBITDA |
0.00 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.34) | 0.40 | (0.06) | (0.39) | (3.16) | (3.16) | (3.16) |
EV/FCF |
(0.31) | 0.39 | (0.06) | (0.36) | (3.06) | (3.06) | (3.06) |
Quick Ratio |
1.70 | 3.96 | 0.94 | 3.48 | 0.48 | 0.17 | 0.12 |
Current Ratio |
2.11 | 4.39 | 1.24 | 3.69 | 0.50 | 0.20 | 0.16 |
Net Debt/EBITDA |
0.31 | 0.50 | 0.16 | 0.46 | 1.15 | (0.16) | (1.45) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 85.34% | 345.55% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.16) | (0.36) |
Asset Turnover |
0.38 | 0.40 | 0.34 | 0.07 | 0.03 | 0.13 | 0.00 |
Operating CF/Net income |
0.86 | 0.72 | 0.78 | 0.64 | 0.61 | 0.29 | 0.46 |
Capex/Depreciation |
(1.93) | (0.28) | (0.85) | (2.93) | (0.89) | — | — |
Interest Coverage |
— | (404.88) | (748.90) | (52.90) | (10.40) | (3.20) | (20.36) |
| (600.05%) | (912.45%) | (443.27%) | 264.57% | 58.83% | 16.06% | 0.00% | |
| (121.89%) | (168.93%) | (178.74%) | (185.82%) | (145.88%) | (177.49%) | 0.00% | |
ROIC |
(622.66%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(280.71%) | (192.77%) | (911.17%) | (248.58%) | 93.96% | 49.14% | 35.87% |
Average Days of Receivables |
157.14 | 96.12 | 64.57 | 120.43 | 173.38 | 120.83 | 366.36 |
Research and Development Expense of Revenue |
54.49% | 79.43% | 108.03% | 409.26% | 1,073.75% | 504.34% | 693.10% |
Selling, General and Administrative Expense of Revenue |
329.64% | 392.86% | 471.48% | 2,207.81% | 3,030.00% | 778.54% | 368.10% |
Intangible Assets out of Total Assets |
0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
42.88% | 117.33% | 141.56% | 419.25% | 235.63% | 37.90% | 0.00% |
Graham Net Nets |
0.15 | 1.90 | (0.59) | 0.35 | (0.43) | (0.43) | (0.43) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 183,875.17 | 0.00 | 0.00 |
Earnings Yield |
(208.82%) | (597.68%) | (627.76%) | (251.95%) | (44.31%) | (44.31%) | (44.31%) |
Free Cash Flow Yield |
(166.70%) | (440.77%) | (444.67%) | (99.70%) | (27.08%) | (27.08%) | (27.08%) |
Revenue per Share |
18.67 | 94.44 | 450.46 | 238.28 | 533.33 | 146.00 | 0.05 |
Operating CF per Share |
(50.88) | (284.67) | (1,874.31) | (4,146.55) | (14,306.67) | (558.00) | (0.21) |
Capex per Share |
(4.84) | (5.36) | (55.54) | (292.07) | (340.00) | 0.00 | 0.00 |
Free Cash Flow per Share |
(55.72) | (290.03) | (1,929.85) | (4,438.62) | (14,646.67) | (558.00) | (0.21) |
Cash per Share |
17.78 | 188.33 | 373.54 | 2,955.17 | 24,403.33 | 818.67 | 0.14 |
Shareholders Equity per Share |
23.86 | 172.07 | 119.69 | 2,155.86 | (23,043.33) | (7,123.00) | (2.32) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
23.86 | 172.07 | 119.69 | 2,155.86 | (23,043.33) | (7,123.00) | (2.32) |
Free Cash Flow |
(11.77) | (10.06) | (12.54) | (12.87) | (4.39) | (0.17) | (0.24) |
Working Capital |
3.56 | 6.34 | 0.75 | 6.82 | (7.60) | (1.19) | (1.42) |
Capital Expenditures |
(1.02) | (0.19) | (0.36) | (0.85) | (0.10) | — | — |
Net Current Asset Value |
1.05 | 4.34 | (1.68) | 4.51 | (8.51) | (1.52) | (1.61) |
EV/EBIT |
0.00 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.26 | 0.06 | 0.12 | 1.23 | 0.64 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.58 | 0.87 | 0.44 | 0.36 | 1.13 | — | — |
Cash ROIC |
(133.79%) | (80.47%) | (391.27%) | (86.84%) | (1,076.96%) | 10.75% | 15.38% |
Accounts Receivable Turnover |
3.08 | 4.75 | 7.85 | 4.55 | 3.54 | 1.28 | 0.00 |
Accounts Payable Turnover |
2.61 | 3.91 | 3.43 | 2.59 | 0.10 | 0.04 | 0.00 |
Inventory Turnover |
1.91 | 2.70 | 3.48 | 4.42 | 0.48 | 0.35 | 0.00 |
Average Days of Payables |
194.47 | 86.01 | 93.68 | 150.71 | 3,172.18 | 11,751.80 | 8,925.55 |
Days of Inventory on Hand |
242.57 | 141.25 | 119.86 | 113.72 | 1,247.64 | 863.63 | 1,226.64 |
Average Receivables |
1.28 | 0.69 | 0.37 | 0.15 | 0.05 | 0.03 | — |
Average Payables |
0.61 | 0.40 | 0.49 | 0.51 | 0.53 | 0.52 | — |
Average Inventory |
0.83 | 0.58 | 0.48 | 0.30 | 0.12 | 0.05 | — |
Average Assets |
10.30 | 8.09 | 8.72 | 10.18 | 4.83 | 0.33 | — |
Average Common Equity |
2.09 | 1.50 | 3.52 | (7.15) | (11.98) | (3.64) | — |
Columns are period end dates